Using Off-Label Communications to Responsibly Advance the Public Health

被引:0
|
作者
Peter J. Pitts
机构
[1] Center for Medicine in the Public Interest,
来源
Therapeutic Innovation & Regulatory Science | 2017年 / 51卷
关键词
DTC; off-label communication; Amarin; Caronia; free speech;
D O I
暂无
中图分类号
学科分类号
摘要
The debate over off-label communications doesn’t begin or end with the Caronia or Amarin decisions. It’s a continuing dialogue between manufacturers and the FDA, between doctors and patients, between doctors and academics, between lawyers and judges, and between advocates on all sides. And the red thread that ties these conversations together is responsible off-label communications. Not sales strategies. Not Direct-to-Consumer (DTC) advertising and marketing tactics. Not managed market negotiations—the responsible sharing of truthful and accurate information via nonregulated speech. Off-label communications, properly done, advances precision medicine, delivering speedier positive patient outcomes and reducing costs to our health care system. Off-label communications provides patients with more options for effective medicines.
引用
收藏
页码:322 / 326
页数:4
相关论文
共 50 条
  • [41] Off-label, off-limits? Parental awareness and attitudes towards off-label use in paediatrics
    Lenk, Christian
    Koch, Philipp
    Zappel, Hildegard
    Wiesemann, Claudia
    EUROPEAN JOURNAL OF PEDIATRICS, 2009, 168 (12) : 1473 - 1478
  • [42] Quetiapine: off-label prescribing in a community mental health team
    Abdelgadir, Ala
    Walsh, Richard
    Walsh, Elizabeth
    Patel, Sonn
    BJPSYCH OPEN, 2021, 7 : S63 - S64
  • [43] Mitochondria and the Repurposing of Diabetes Drugs for Off-Label Health Benefits
    Yip, Joyce Mei Xin
    Chiang, Grace Shu Hui
    Lee, Ian Chong Jin
    Lehming-Teo, Rachel
    Dai, Kexin
    Dongol, Lokeysh
    Wang, Laureen Yi-Ting
    Teo, Denise
    Seah, Geok Teng
    Lehming, Norbert
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (01)
  • [44] Electronic Health Records and Drugs Prescribed for Off-label Indications
    Porter, Charles B.
    MAYO CLINIC PROCEEDINGS, 2017, 92 (04) : 683 - 684
  • [45] In Defense of Off-label Prescribing
    Keller, David L.
    JAMA INTERNAL MEDICINE, 2016, 176 (06) : 861 - 861
  • [46] Off-Label Amitriptyline for Insomnia
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2023, 65 (1672): : 48 - 48
  • [47] Ethics of off-label treatment
    Atkins, CD
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) : 1637 - 1637
  • [48] Off-Label Therapy in Rheumatology
    Krueger, K.
    Sieper, J.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2012, 71 (02): : 99 - 100
  • [49] Off-Label Antidepressant Use
    Schaefer, Wiebke
    Kollhorst, Bianca
    Reinders, Tammo
    Riedel, Oliver
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 465 - 466
  • [50] PUBLIC REIMBURSEMENT OF PRESCRIPTION DRUGS USED FOR OFF-LABEL INDICATIONS IN ONTARIO
    Rawson, Nigel S. B.
    Chhabra, Arpit
    JOURNAL OF POPULATION THERAPEUTICS AND CLINICAL PHARMACOLOGY, 2018, 25 (02): : E23 - E30